AR118580A1 - Formulación de tableta vaginal - Google Patents

Formulación de tableta vaginal

Info

Publication number
AR118580A1
AR118580A1 ARP200100936A ARP200100936A AR118580A1 AR 118580 A1 AR118580 A1 AR 118580A1 AR P200100936 A ARP200100936 A AR P200100936A AR P200100936 A ARP200100936 A AR P200100936A AR 118580 A1 AR118580 A1 AR 118580A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
tablet formulation
vaginal tablet
vaginal
glucono
Prior art date
Application number
ARP200100936A
Other languages
English (en)
Inventor
Annette Sfholm
Nils Lindberg
- Strevens Helena Olof
Olov Sterner
Sophie Manner
Ulf Ellervik
Original Assignee
Gedea Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gedea Biotech Ab filed Critical Gedea Biotech Ab
Publication of AR118580A1 publication Critical patent/AR118580A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina

Abstract

La presente se refiere a una composición farmacéutica que comprende glucono d-lactona, que es adecuada para uso en el tratamiento de infecciones microbianas vaginales. Reivindicación 1: Una composición farmacéutica adecuada para administración vaginal, en donde la composición farmacéutica comprende a) de 5 a 30% p/p de Glucono d-lactona (GDL); y b) de 10 a 40% p/p de Hipromelosa (HPMC). Reivindicación 2: La composición farmacéutica de acuerdo con la reivindicación 1, en donde la composición farmacéutica es una tableta.
ARP200100936A 2019-04-05 2020-04-03 Formulación de tableta vaginal AR118580A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19167495 2019-04-05

Publications (1)

Publication Number Publication Date
AR118580A1 true AR118580A1 (es) 2021-10-20

Family

ID=66101895

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200100936A AR118580A1 (es) 2019-04-05 2020-04-03 Formulación de tableta vaginal

Country Status (24)

Country Link
US (1) US20220193031A1 (es)
EP (1) EP3976000B1 (es)
JP (1) JP2022537478A (es)
KR (1) KR20210148195A (es)
CN (1) CN113660928B (es)
AR (1) AR118580A1 (es)
AU (1) AU2020252268A1 (es)
BR (1) BR112021019999A2 (es)
CA (1) CA3134086A1 (es)
CL (1) CL2021002430A1 (es)
CO (1) CO2021014253A2 (es)
EA (1) EA202192716A1 (es)
ES (1) ES2961736T3 (es)
HU (1) HUE062772T2 (es)
IL (1) IL286942A (es)
MA (1) MA56011A (es)
MX (1) MX2021012146A (es)
PE (1) PE20220381A1 (es)
PL (1) PL3976000T3 (es)
SG (1) SG11202110236QA (es)
TW (1) TW202103693A (es)
UA (1) UA127823C2 (es)
WO (1) WO2020201515A1 (es)
ZA (1) ZA202106877B (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0956858B1 (en) * 1998-04-30 2001-10-31 Renata Maria Anna Cavaliere Vesely Pharmaceutical compositions containing Lactobacillus brevis and Lactobacillus salivarius for treatment of vaginal infections
US6287599B1 (en) * 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
US20030017207A1 (en) * 2001-05-01 2003-01-23 Lin Shun Y. Compositions and methods for treating vulvovaginitis and vaginosis
ITBO20110461A1 (it) * 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
SG11201807475VA (en) * 2016-04-06 2018-10-30 Gedea Biotech Ab Glucono delta-lactone for treatment of vaginal fungal infections
US11612584B2 (en) 2017-10-06 2023-03-28 Gedea Biotech Ab Gluconic acid derivatives for use in the treatment and/or prevention of microbial infections

Also Published As

Publication number Publication date
BR112021019999A2 (pt) 2021-12-07
CA3134086A1 (en) 2020-10-08
EP3976000B1 (en) 2023-08-02
MX2021012146A (es) 2021-12-10
CN113660928A (zh) 2021-11-16
WO2020201515A1 (en) 2020-10-08
AU2020252268A1 (en) 2021-10-21
TW202103693A (zh) 2021-02-01
PL3976000T3 (pl) 2023-12-04
IL286942A (en) 2021-12-01
JP2022537478A (ja) 2022-08-26
PE20220381A1 (es) 2022-03-18
ZA202106877B (en) 2023-03-29
CO2021014253A2 (es) 2021-11-19
EA202192716A1 (ru) 2022-01-17
CL2021002430A1 (es) 2022-07-01
ES2961736T3 (es) 2024-03-13
KR20210148195A (ko) 2021-12-07
HUE062772T2 (hu) 2023-12-28
CN113660928B (zh) 2024-04-05
EP3976000C0 (en) 2023-08-02
US20220193031A1 (en) 2022-06-23
EP3976000A1 (en) 2022-04-06
UA127823C2 (uk) 2024-01-10
MA56011A (fr) 2022-04-06
SG11202110236QA (en) 2021-10-28

Similar Documents

Publication Publication Date Title
PE20210401A1 (es) Composiciones farmaceuticas que comprenden meloxicam
CY1109910T1 (el) Χρηση μιας υδροφιλης μητρας η οποια περιεχει ενα παραγωγο πολυακρυλικου οξεος, εναν αιθερα κυτταρινης και εναν παραγοντα αποσαθρωσης για την παραγωγη ενος φαρμακου για την αγωγη ασθενειων των γυναικειων γεννητικων οργανων
CL2016001411A1 (es) Unidad de dosificación farmacéutica solida de desintegración oral que comprende un componente de estetrol; metodo de preparación; uso para la anticoncepción femenina y en terápia de sustitución hormonal femenina.
CL2020002252A1 (es) Formulación oftálmica.
CO2020009524A2 (es) Formulación de adenovirus del grupo b
AR115913A1 (es) Formas de dosificación oral biodisponibles, uso, métodos
CY1125075T1 (el) Εκχυλισμα salvia haenkei σαν δραστικος παραγοντας στις διαδικασιες επανεπιθηλιωσης και επουλωσης ιστων
AR118580A1 (es) Formulación de tableta vaginal
TR201904382T4 (tr) Vajinit tedavisi.
CO2023005726A2 (es) Formulación sólida
CL2018002705A1 (es) Glucono delta-lactona para el tratamiento de infecciones fúngicas vaginales
CL2022003426A1 (es) Composición farmacéutica acuosa de levilimab y su uso
MX2015016679A (es) Formulaciones de agomelatina que comprenden agomelatina en forma de cocristales.
CO2022002493A2 (es) Nanoemulsion de ácido 18p-glicirretínico
MY191983A (en) Pharmaceutical formulations comprising sodium palmitoyl-l-prolyl-l-prolyl-glycyl-l-tyrosinate and methods for preparing the same
PL425832A1 (pl) Genisteina oraz jej kompozycja do zastosowania w leczeniu choroby Alzheimera
MX2023006235A (es) Composiciones para administracion de farmacos y metodos de uso de las mismas.
HRP20221338T1 (hr) Primjena totarola i farmaceutski pripravak koji sadrži totarol
MX2020004105A (es) Formulacion farmaceutica.
AR117298A1 (es) Aglutinante de péptido
BR112021026471A2 (pt) Formulações de dose sólida para a liberação sem agulha
UA130743U (uk) Фармацевтична композиція антидіабетичної дії у формі матричних таблеток
ECSP23031196A (es) Composición farmacéutica adecuada para administración vaginal en forma de óvulos y uso de la misma
MX2021004553A (es) Composiciones farmaceuticas y metodos para fabricar formulaciones de dosificacion solidas bajo demanda.
CL2021001076A1 (es) Composición farmacéutica que comprende una combinación de 1,3-2,5% de tetrahidrocannabinol (thc) y 0,6-1,4% de cannabidiol (cbd); su proceso de elaboración; y su uso para el tratamiento del dolor crónico refractario.